NCT07017673 - Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 25, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

November 30, 2032

Conditions

TNBCTNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast Carcinoma

Interventions

DRUG

Ivonescimab

Drug: Ivonescimab Dose: 20 mg/kg Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)

DRUG

Carboplatin

Drug: Carboplatin Dose: AUC6 Route: IV infusion Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)

DRUG

Docetaxel

Drug: Docetaxel Dose: 75 mg/m\^2 Route: IV infusion over 60 minutes Frequency: Q3W Duration: 6 cycles (Each cycle is 21 days)

Trial Locations (4)

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

RECRUITING

Cedars-Sinai Medical Center Beverly Hills, Los Angeles

RECRUITING

Hunt Cancer Institute, an Affiliate of CS Cancer, Torrance

NOT_YET_RECRUITING

Huntington Cancer Center, an Affiliate of CS Cancer, Pasadena